Centinel Spine Marks 100th prodisc C Vivo Implant

Less than two months after Centinel Spine LLC’s prodisc C Vivo Cervical Total Disc Replacement (TDR) made its clinical debut, the company marked  the product’s 100th implant.

Centinel Spine achieved the milestone within six weeks of the prodisc C Vivo’s first U.S. implant on Sept. 7. During that period, the company trained over 70 surgeons, and more than 30 new surgeons are now using the system.
 
“I have had the opportunity to use the prodisc C Vivo system multiple times and this device offers unique benefits to the surgeon and the patient. Because the Vivo implant is keel-less and incorporates a streamlined surgical technique, I have found that I am able to reduce the number of X-rays required during implantation of the device,” said Kevin Rutz, M.D., a spine surgeon from St. Louis, Mo. “This is a benefit to both the patient as well as the staff in the operating room. I have also found that making intra-operative adjustments to the positioning of the implant is easier with the Vivo device than other total discs that I have used in the past.”

The prodisc C Vivo system has been in clinical use internationally since 2009 and is currently one of the most frequently implanted TDR devices in the world. The device has keel-less fixation and combines a unique anatomically-designed superior endplate with lateral spikes to optimize fit and provide immediate fixation. Similar to all prodisc products, the prodisc C Vivo device incorporates prodisc CORE technology, the basis behind the predictable clinical outcomes of the prodisc platform after 30 years and more than 225,000 implantations worldwide.*
 
“Degenerative disc disease is a leading cause of pain and disability in the U.S. and around the world,” Centinel Spine CEO Steve Murray said. “Providing total disc replacement solutions that can match individual patient anatomy is an important step in addressing this all-too-prevalent condition. We are pleased to see surgeons rapidly adopting the prodisc C Vivo technology knowing that many patients are benefiting from our broadened total disc portfolio.”
 
“The prodisc C Vivo system incorporates the simplicity of a keel-less disc replacement implant without sacrificing stability, an issue seen in many other implants. This is the best of both worlds in disc replacement and will rapidly be adopted by surgeons who embrace motion preservation,” said Adam Bruggeman, M.D., a spine surgeon from San Antonio, Texas. 
 
Centinel Spine’s cervical TDR portfolio includes four devices approved by the U.S. Food and Drug Administration for 1-level indications, offering the broadest spectrum of solutions to address surgeon preference and individual patient anatomy.
 
Centinel Spine is a global medical device company addressing cervical and lumbar spinal disease through anterior surgical access. The company offers a continuum of brand-name, motion-preserving and fusion solutions backed by more than 30 years of clinical success—providing the most robust and clinically-proven technology platforms in the world for total disc replacement (prodisc®) and Integrated Interbody fusion (STALIF). Centinel Spine claims it is the only company with motion-preserving and fusion solutions for both cervical and lumbar anterior column reconstruction.

* Data on file.